Correction to: Amitifadine, a triple reuptake inhibitor, reduces self-administration of the opiate remifentanil in rats.
| dc.contributor.author | Levin, Edward D | |
| dc.contributor.author | Wells, Corinne | |
| dc.contributor.author | Hawkey, Andrew | |
| dc.contributor.author | Holloway, Zade | |
| dc.contributor.author | Blair, Graham | |
| dc.contributor.author | Vierling, Alexander | |
| dc.contributor.author | Ko, Ashley | |
| dc.contributor.author | Pace, Caroline | |
| dc.contributor.author | Modarres, John | |
| dc.contributor.author | McKinney, Anthony | |
| dc.contributor.author | Rezvani, Amir H | |
| dc.contributor.author | Rose, Jed E | |
| dc.date.accessioned | 2023-12-06T15:15:21Z | |
| dc.date.available | 2023-12-06T15:15:21Z | |
| dc.date.issued | 2021-04 | |
| dc.date.updated | 2023-12-06T15:15:20Z | |
| dc.description.abstract | Our article published in Psychopharmacology had a typographical error in the units of remifentanil infusion for selfadministration. The correct infusion dose of remifentanil is 0.3 µg/kg/infusion not 0.3 mg/kg/infusion. | |
| dc.identifier | 10.1007/s00213-021-05794-y | |
| dc.identifier.issn | 0033-3158 | |
| dc.identifier.issn | 1432-2072 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | Springer Science and Business Media LLC | |
| dc.relation.ispartof | Psychopharmacology | |
| dc.relation.isversionof | 10.1007/s00213-021-05794-y | |
| dc.title | Correction to: Amitifadine, a triple reuptake inhibitor, reduces self-administration of the opiate remifentanil in rats. | |
| dc.type | Journal article | |
| duke.contributor.orcid | Levin, Edward D|0000-0002-5060-9602 | |
| pubs.begin-page | 1227 | |
| pubs.issue | 4 | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | Nicholas School of the Environment | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Trinity College of Arts & Sciences | |
| pubs.organisational-group | Basic Science Departments | |
| pubs.organisational-group | Clinical Science Departments | |
| pubs.organisational-group | Institutes and Centers | |
| pubs.organisational-group | Pharmacology & Cancer Biology | |
| pubs.organisational-group | Psychiatry & Behavioral Sciences | |
| pubs.organisational-group | Duke Cancer Institute | |
| pubs.organisational-group | Psychology & Neuroscience | |
| pubs.organisational-group | Environmental Sciences and Policy | |
| pubs.organisational-group | Institutes and Provost's Academic Units | |
| pubs.organisational-group | University Institutes and Centers | |
| pubs.organisational-group | Duke Institute for Brain Sciences | |
| pubs.organisational-group | Initiatives | |
| pubs.organisational-group | Duke Science & Society | |
| pubs.organisational-group | Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences | |
| pubs.publication-status | Published | |
| pubs.volume | 238 |
Files
Original bundle
- Name:
- Amitifdine-remiSA-correction-Psychopharm-21.pdf
- Size:
- 101.78 KB
- Format:
- Adobe Portable Document Format
- Description:
- Published version